Freeze-dried Live Attenuated Hepatitis A Vaccine (6.5ccid50) (Medical Monograph)

Overview

A single-dose, live attenuated viral vaccine derived from the H2 strain of Hepatitis A virus, propagated in human diploid cells (KMB17 or 2BS). The 6.5ccid50 (50% cell culture infectious dose) represents the viral titer per dose. It provides active immunization against Hepatitis A virus (HAV) infection by inducing a protective immune response. It is a critical tool in public health for endemic regions like India.

Uses

  • Active immunization against Hepatitis A virus infection in individuals from 12 months of age and above.
  • Routine childhood immunization in endemic areas like India.
  • Outbreak control in communities and closed settings (e.g., schools, military).

Side Effects

  • Pain, tenderness, redness, or swelling at the injection site.
  • Low-grade fever (<38.5°C).
  • Malaise, fatigue, headache.
  • Loss of appetite, nausea.

Detailed Pharmacology

The vaccine contains live Hepatitis A virus (H2 strain) that has been attenuated (weakened) to lose its pathogenicity but retain its immunogenicity. Upon subcutaneous administration, the virus infects local cells and undergoes limited replication, presenting viral antigens to the host's immune system. This stimulates both humoral (B-cell) and cell-mediated (T-cell) immune responses, leading to the production of neutralizing antibodies (primarily anti-HAV IgG) and memory B and T cells.

Available Brands in India

BrandManufacturerPrice
Biovac-A Wockhardt Limited ₹1200 - ₹1800 per dose (Hospital/Clinic price)
Havisure Zydus Cadila (now Zydus Lifesciences) ₹1100 - ₹1700 per dose (Hospital/Clinic price)
Avaxim Sanofi India Limited ₹1800 - ₹2500 per dose (2-dose schedule)